The UK and US have concluded a important trade agreement that will preserve no import taxes on British pharmaceutical products going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost funding on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these crucial goods will stay at nothing for a timeframe of the next three years.
This development is in response to earlier statements to hike import taxes on branded pharmaceutical products, with increases floated reaching double the cost.
"This deal between the United Kingdom bolsters the global environment for new treatments and brings much-needed equity to American-British drug exports," an announcement noted.
Commercial Importance
Medicines represent one of the UK's largest export categories to the United States, which is clearly the biggest buyer for major British pharmaceutical firms.
Export figures indicate that in the year prior to the third quarter, the UK exported medicines totaling billions to the US. This amount accounted for a significant portion of all goods exports in that span.
"This guarantee secures work, stimulates capital expenditure and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement involves several notable commitments from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must pay back to the NHS to control costs will be capped at 15%. In the past, refunds topped twenty percent.
Broader Context
This agreement comes amid a long-running tension between the sector and the ministers over spending levels and NHS adoption.
These tensions were heightened by claims that US customers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or cancelled, while major funding commitments have been pledged toward American operations.
The Science Minister stated that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
